Aileron Therapeutics Inc (NASDAQ:ALRN) Can’t Be More Risky. Short Interest Increased

April 17, 2018 - By Louis Casey

The stock of Aileron Therapeutics Inc (NASDAQ:ALRN) registered an increase of 72.81% in short interest. ALRN’s total short interest was 110,600 shares in April as published by FINRA. Its up 72.81% from 64,000 shares, reported previously. With 42,300 shares average volume, it will take short sellers 3 days to cover their ALRN’s short positions. The short interest to Aileron Therapeutics Inc’s float is 2.58%.

The stock increased 0.43% or $0.03 during the last trading session, reaching $6.99. About 16,694 shares traded. Aileron Therapeutics, Inc. (NASDAQ:ALRN) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing a novel class of therapeutics in the United States. The company has market cap of $102.99 million. The companyÂ’s lead product includes ALRN-6924, a stapled peptide that in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial for the treatment of peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia and advanced myelodysplastic syndrome (MDS); and Phase II b trial for the treatment of AML/MDS in combination with cytosine arabinoside. It currently has negative earnings. It is also developing next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.